Healthcare ❯ Clinical Trials

Phase 3 Trials

Drug Efficacy Efficacy Studies Efficacy and Safety Intervention Studies Checkpoint Inhibitors Patient Adherence Drug Development SYNCHRONY Programme Regulatory Milestones Solid Tumors Treatment Efficacy Obesity Treatments Weight Loss Trials Focal Onset Seizures TRIUMPH-1 Trial DURAVYU Drug Approval Process

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

LUCIA's late-2026 readout now determines whether EyePoint can pursue a U.S. approval or a commercial launch.

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Weekly Oral Risperidone Pill Maintains Steady Levels in Phase 3 Schizophrenia Trial

Inherited Mitochondrial Variant Linked to Checkpoint Inhibitor Resistance in Metastatic Melanoma